2023 World Conference on Lung Cancer (Posters)-EP04.01. Detecting KRAS Mutations in Peripheral Blood Extracellular Vesicles in Non-Small Cell Lung Cancer Using Digital Droplet PCR

EP04.01. Detecting KRAS Mutations in Peripheral Blood Extracellular Vesicles in Non-Small Cell Lung Cancer Using Digital Droplet PCR - PDF(Slides)

Back to course

Pdf Summary

Researchers from the University of Queensland Thoracic Research Centre in Australia conducted a study to determine if KRAS mutations could be detected in extracellular vesicles (EVs) in the blood of patients with non-small cell lung cancer (NSCLC) using droplet digital PCR (ddPCR). NSCLC is one of the leading causes of cancer-related mortality globally. Traditionally, somatic mutations are detected through invasive biopsies, but this study aimed to explore the potential of using EVs in the blood for mutation screening.<br /><br />The study involved collecting blood samples from NSCLC patients with known KRAS mutations, as well as those with wild type KRAS. The plasma, apoptotic bodies (ABs), microvesicles (MVs), and exosomes from the blood samples were enriched and subjected to DNA extraction and concentration. The researchers then performed ddPCR analysis using a KRAS G12/G13 Screening kit to detect KRAS mutations.<br /><br />The results showed that there was low sensitivity for somatic KRAS mutation detection in early-stage NSCLC using ABs, MVs, processed plasma, and exosomes. However, in late-stage NSCLC, KRAS mutations were detectable in microvesicles, processed plasma, and exosomes, with processed plasma showing the highest concordance to the primary tumor genotype.<br /><br />Overall, the study did not support the use of ABs, MVs, or exosomes as liquid biopsy templates for detecting KRAS mutations in NSCLC. However, processed plasma showed promise in detecting KRAS mutations in late-stage disease.<br /><br />It is important to note that this study was a pilot study, and further testing is required to confirm the KRAS mutation status for some samples. The study provides insights into the potential use of EVs in blood for mutation screening in NSCLC, specifically in late-stage disease.

Asset Subtitle

Caeli Zahra

Meta Tag

Speaker Caeli Zahra

Topic Screening & Early Detection: Biomarkers/Imaging Technology

Keywords

University of Queensland Thoracic Research Centre

Australia

KRAS mutations

extracellular vesicles

blood

non-small cell lung cancer

droplet digital PCR

somatic mutations

invasive biopsies

liquid biopsy templates